Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.
Saved in:
| Title: | Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study. |
|---|---|
| Authors: | Elimova, Elena1 (AUTHOR) elena.elimova@uhn.ca, Ajani, Jaffer2 (AUTHOR), Burris, Howard3 (AUTHOR), Denlinger, Crystal S4 (AUTHOR), Iqbal, Syma5 (AUTHOR), Kang, Yoon-Koo6 (AUTHOR), Kim, Jwa Hoon7 (AUTHOR), Lee, Keun-Wook8 (AUTHOR), Lin, Bruce9 (AUTHOR), Mehta, Rutika10 (AUTHOR), Oh, Do-Youn11 (AUTHOR), Rha, Sun Young12 (AUTHOR), Seol, Young Mi13 (AUTHOR), Yang, Lin14 (AUTHOR), Ozog, Mark A14 (AUTHOR), Garfin, Phillip M14 (AUTHOR), Ku, Geoffrey15 (AUTHOR) |
| Source: | Lancet Oncology. Jul2025, Vol. 26 Issue 7, p847-859. 13p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
